Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
453 34
Ultima descărcare din IBN:
2021-04-12 18:35
Căutarea după subiecte
similare conform CZU
616.155.392-07-036.1-08 (1)
Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (633)
SM ISO690:2012
TOMACINSCHII, Victor; ROBU, Maria; CORCIMARU, Ion; MUSTEAŢĂ, Vasile; MUSTEAŢĂ, Larisa; BURUIANA, Sanda; SPORÎŞ, Natalia; POPESCU, Maria. Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale. 2018, nr. 2-3(59-60), pp. 61-65. ISSN 1857-0011.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale
Numărul 2-3(59-60) / 2018 / ISSN 1857-0011

Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.

Clinical aspects and treatment outcomes of chronic lymphocytic leukemia.

Клинические аспекты и результаты лечения хронического лимфолейкоза.


CZU: 616.155.392-07-036.1-08
Pag. 61-65

Tomacinschii Victor1, Robu Maria1, Corcimaru Ion1, Musteaţă Vasile12, Musteaţă Larisa1, Buruiana Sanda12, Sporîş Natalia21, Popescu Maria12
 
1 Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“,
2 IMSP Institutul Oncologic
 
Disponibil în IBN: 4 ianuarie 2019


Rezumat

Au fost analizate particularitaţile evoluţiei clinice, prognostice și rezultatele nemijlocite ale tratamentului pe un lot de 118 pacienţi cu leucemie limfocitară cronică. Leucemia limfocitară cronică mai frecvent s-a dezvoltat la persoane cu vârsta 55-75 ani(69,4%), aproximativ cu aceeași frecvență la bărbați și femei(51% și 49% respectiv). S-a dovedit, că tratamentul cu utilizarea regimurilor terapeutice noi crește rata răspunsului la tratament și îmbunătăţeşte calitatea vieţii pacienţilor.

The peculiarities of clinical evolution, prognosis and immediate treatment outcomes were analyzed in a group of 118 patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia more frequently developed in patients aged between 55-75 years (69.4%), approximately with the same frequency in males and females (51% and 49%, respectively). It has been shown that treatment with new therapeutic regimens improves the rate of response to treatment and patients quality of life.

Изучены особенности клинического течения, непосредственные результаты лечения и прогноз у 118 пациентов с хроническим лимфолейкозом. Заболевание чаще (69,4%) диагностировали у лиц в возрасте от 55 до 75 лет примерно с одинаковой частотой у мужчин и женщин (51% и 49%, соответственно). Лечение современными химиотерапевтическими режимами увеличивает частоту ремиссий и улучшает качество жизни пациентов.

Cuvinte-cheie
leucemie limfocitară cronică, evoluție clinică, prognostic, tratament.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-70211</cfResPublId>
<cfResPublDate>2018-12-25</cfResPublDate>
<cfVol>59-60</cfVol>
<cfIssue>2-3</cfIssue>
<cfStartPage>61</cfStartPage>
<cfISSN>1857-0011</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/70211</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'><p>Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.</p></cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>leucemie limfocitară cronică; evoluție clinică; prognostic; tratament.</cfKeyw>
<cfAbstr cfLangCode='RO' cfTrans='o'><p>Au fost analizate particularitaţile evoluţiei clinice, prognostice și rezultatele nemijlocite ale tratamentului pe un lot de 118 pacienţi cu leucemie limfocitară cronică. Leucemia limfocitară cronică mai frecvent s-a dezvoltat la persoane cu v&acirc;rsta 55-75 ani(69,4%), aproximativ cu aceeași frecvență la bărbați și femei(51% și 49% respectiv). S-a dovedit, că tratamentul cu utilizarea regimurilor terapeutice noi crește rata răspunsului la tratament și &icirc;mbunătăţeşte calitatea vieţii pacienţilor.</p></cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The peculiarities of clinical evolution, prognosis and immediate treatment outcomes were analyzed in a group of 118 patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia more frequently developed in patients aged between 55-75 years (69.4%), approximately with the same frequency in males and females (51% and 49%, respectively). It has been shown that treatment with new therapeutic regimens improves the rate of response to treatment and patients quality of life.</p></cfAbstr>
<cfAbstr cfLangCode='RU' cfTrans='o'><p>Изучены особенности клинического течения, непосредственные результаты лечения и прогноз у 118 пациентов с хроническим лимфолейкозом. Заболевание чаще (69,4%) диагностировали у лиц в возрасте от 55 до 75 лет примерно с одинаковой частотой у мужчин и женщин (51% и 49%, соответственно). Лечение современными химиотерапевтическими режимами увеличивает частоту ремиссий и улучшает качество жизни пациентов.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-60743</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11551</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11697</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11430</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11429</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-17453</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-20702</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29191</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-60743</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-60743-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Tomacinschii</cfFamilyNames>
<cfFirstNames>Victor</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11551</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11551-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Robu</cfFamilyNames>
<cfFirstNames>Maria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11697</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11697-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Корчмару</cfFamilyNames>
<cfFirstNames>Ион</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11430</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11430-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Musteaţă</cfFamilyNames>
<cfFirstNames>Vasile</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11429</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11429-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Musteaţă</cfFamilyNames>
<cfFirstNames>Larisa</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-17453</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-17453-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Buruiana</cfFamilyNames>
<cfFirstNames>Sanda</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-20702</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-20702-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Спориш</cfFamilyNames>
<cfFirstNames>Наталья</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29191</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29191-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Popescu</cfFamilyNames>
<cfFirstNames>Maria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>